<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958916</url>
  </required_header>
  <id_info>
    <org_study_id>SCCCG-BL/DLBCL-2017-001</org_study_id>
    <nct_id>NCT03958916</nct_id>
  </id_info>
  <brief_title>Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL</brief_title>
  <official_title>Prospective Multicenters Clinical Cohort Study on Efficacy and Safety of Stratified Treatment for Chinese Children With Burkitt Lymphoma/Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized,
      observational, cohort clinical study with participating centers of the South China Children's
      Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate
      efficacy and safety of stratified treatment based on risk factors of childhood and
      adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research purposes:

        1. To investigate the efficacy and safety of SCCCG-BL/DLBCL-2017 in children with BL and
           DLBCL.

        2. To investigate the effect of rituximab combined with chemotherapy on the survival rate
           of children with high-risk BL/DLBCL.

        3. To investigate the effect of rituximab on immune function in children with high-risk
           BL/DLBCL.

        4. To explore the correlation between MRD detection and the efficacy and survival of
           children with BL/DLBCL.

        5. To explore the role of PET/CT in evaluating residual lesions in children after BL/DLBCL
           treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">May 5, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>through study completion, maximal eight years</time_frame>
    <description>EFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease or relapse, treatment related death, death of any other cause or diagnosis of secondary malignancies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune reconstitution rate (only in intermediate/high risk patients</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>Immune reconstitution rate is defined as percentage of patients achieving age adjusted serum immunoglobulin levels 12 months after start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>through study completion, maximal eight years</time_frame>
    <description>OS is defined as time from start of treatment/randomization up to death of any</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>through study completion, maximal eight years</time_frame>
    <description>RFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease, or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>on an average 3 weeks after finish of treatment</time_frame>
    <description>Complete response, partial remission, objective effect, stable disease or progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>from the first day of protocol defined treatment until two years after start of protocol defined treatment</time_frame>
    <description>Rate of patients with acute toxicity defined as grade III/IV/V AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients achieving normal immunoglobulin level 12 months after start of treatment</measure>
    <time_frame>12 months after start of treatment</time_frame>
    <description>Rate of patients achieving normal immunoglobulin level 12 months after start of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time interval to normal immunoglobulin level</measure>
    <time_frame>through study completion, maximal eight years</time_frame>
    <description>Time interval to normal immunoglobulin level</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Rituximab</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Pediatric Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Burkitt lymphoma/diffuse large B-cell lymphoma patients，age at diagnosis &lt; 18 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &lt; 18 years old

          2. Pathologically confirmed Burkitt lymphoma or diffuse large B-cell lymphoma

          3. Newly diagnosed patients

          4. Informed consent of guardian of children patients

        Exclusion Criteria:

          1. Pathological components with follicular lymphoma

          2. Immunodeficiency Second neoplasm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sun Xiaofei, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Xiao-Fei</last_name>
    <phone>13600099837</phone>
    <phone_ext>+86</phone_ext>
    <email>sunxf@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Zi-Jun</last_name>
    <phone>13609712260</phone>
    <phone_ext>+86</phone_ext>
    <email>zhenzj@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Xiaofei, Master</last_name>
      <phone>13600099837</phone>
      <phone_ext>086</phone_ext>
      <email>sunxf@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, Reiter A, Cairo MS. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015 Jun 20;33(18):2112-8. doi: 10.1200/JCO.2014.59.7203. Epub 2015 May 4.</citation>
    <PMID>25940716</PMID>
  </results_reference>
  <results_reference>
    <citation>Bakhshi S, Radhakrishnan V, Sharma P, Kumar R, Thulkar S, Vishnubhatla S, Dhawan D, Malhotra A. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study. Radiology. 2012 Mar;262(3):956-68. doi: 10.1148/radiol.11110936.</citation>
    <PMID>22357895</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013 Apr;27(5):1174-7. doi: 10.1038/leu.2012.255. Epub 2012 Sep 3.</citation>
    <PMID>22940833</PMID>
  </results_reference>
  <results_reference>
    <citation>Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A; Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010 Jul 1;28(19):3115-21. doi: 10.1200/JCO.2009.26.6791. Epub 2010 Jun 1.</citation>
    <PMID>20516455</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiao-Fei Sun</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

